CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation

被引：0
作者：
Minggui Pan
Monica Santamaria
David B Wollman
机构：
[1] all at the Kaiser Permanente Medical Center,M Pan is an Attending Physician at the Division of Oncology and Hematology, M Santamaria is an Attending Physician at the Department of Pathology and DB Wollman is an Attending Physician at the Department of Radi
[2] Santa Clara,undefined
[3] CA,undefined
[4] USA.,undefined
来源：
Nature Clinical Practice Oncology | 2007年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
For patients with non-small-cell lung cancer (NSCLC) and brain metastasis, effective treatment strategies are required because systemic chemotherapy is usually ineffective. Pan and colleagues present the case of a 73-year-old man who was diagnosed with NSCLC with brain metastasis, who carried anEGFR mutation and was managed with erlotinib and whole-brain irradiation. The authors discuss the treatment options for patients with metastatic NSCLC and propose erlotinib as an appropriate therapy for patients with a high probability of harboring classic EGFRmutations.
引用
收藏
页码：603 / 607
页数：4
相关论文
共 19 条
[1]  
Pao W(2005)Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non–small cell lung cancer: current knowledge and future directions J Clin Oncol 23 2556-2568
[2]  
Janne P(2005)Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology J Clin Oncol 23 3227-3234
[3]  
Lynch TJ(2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129-2139
[4]  
Paez JG(2004) mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497-1500
[5]  
Pao W(2004)EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 13307-13311
[6]  
Miller VA(2004)Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J Clin Oncol 22 1103-1109
[7]  
Shepherd FA(2005)Erlotinib in previously treated non–small-cell lung cancer N Engl J Med 353 123-132
[8]  
Tsao MS(2005)Erlotinib in lung cancer: molecular and clinical predictors of outcome N Engl J Med 353 133-144
[9]  
Schiller J(2002)Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92-98
[10]  
Sandler A(2006)Paclitaxel with or without bevacizumab for metastatic non-small-cell lung cancer N Engl J Med 355 2542-2550
12